Severe hepatic injury due to Xiaojin capsules (小金胶囊)
10.3760/cma.j.cn114015-20201222-01268
- VernacularTitle:小金胶囊致重度肝损伤
- Author:
Xiaoqin DENG
1
;
Qiong CHEN
1
;
Dongfang SHEN
1
;
Yin HU
1
;
Helang TAN
1
Author Information
1. 重庆市忠县人民医院药剂科，重庆 404399
- Publication Type:Journal Article
- Keywords:
Chemical and drug induced liver injury;
Xiaojin capsules
- From:
Adverse Drug Reactions Journal
2021;23(8):438-440
- CountryChina
- Language:Chinese
-
Abstract:
A 32-year-old male patient with hyperplasia of mammary glands took 5 Rupishu tablets (乳癖舒片) orally thrice daily by himself for about 2 years. Due to the poor treatment effect, he received additional 7 Xiaojin capsules orally twice daily according to the doctor′s advice. The patient′s liver function was normal during the monotherapy with Rupishu tablets. After 50 days of medication with the 2 drugs, the patient developed dark urine and yellowish skin and pruritus. Twelve days later, laboratory tests showed alanine aminotransferase (ALT) 1 068 U/L, aspartate aminotransferase (AST) 562 U/L, total bilirubin (TBil) 106.9 μmol/L, direct bilirubin (DBil) 84 μmol/L, and alkaline phosphatase (ALP) 175 U/L. He was diagnosed as having severe drug-induced liver injury, which was considered to be associated with Xiaojin capsules. Then both drugs were discontinued. Magnesium isoglycyrrhizinate injection and adenosylmethionine for injection were given for liver protection. Twelve days later, laboratory tests showed ALT 163 U/L, AST 52 U/L, TBil 36.1μmol/L, DBil 21.7μmol/L, and ALP 142 U/L. After that, the patient took the above 2 drugs by himself again. Twenty days later, the symptoms above-mentioned and abnormal liver function recurred. Xiaojin capsules were stopped and anti-inflammatory and liver-protective treatments were given. Twenty-three days later, laboratory tests showed ALT 25 U/L, AST 19 U/L, TBil 14.3 μmol/L, DBil 3.6 μmol/L, and ALP 76 U/L.
